Imperial College London
Portrait Picture

ProfessorIainMcNeish

Faculty of Medicine, Department of Surgery & Cancer

Chair in Oncology
 
 
 
//

Contact

 

+44 (0)20 7594 2185i.mcneish Website

 
 
//

Assistant

 

Ms Sophie Lions +44 (0)20 7594 2792

 
//

Location

 

G036Institute of Reproductive and Developmental BiologyHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Bagnoli:2019:10.3390/cells8030200,
author = {Bagnoli, M and Shi, TY and Gourley, C and Speiser, P and Reuss, A and Nijman, HW and Creutzberg, CL and Scholl, S and Negrouk, A and Brady, MF and Hasegawa, K and Oda, K and McNeish, IA and Kohn, EC and Oza, AM and MacKay, H and Millan, D and Bennett, K and Scott, C and Mezzanzanica, D},
doi = {10.3390/cells8030200},
journal = {Cells},
title = {Gynecological cancers translational, research implementation, and harmonization: Gynecologic Cancer InterGroup consensus and still open questions},
url = {http://dx.doi.org/10.3390/cells8030200},
volume = {8},
year = {2019}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - In the era of personalized medicine, the introduction of translational studies in clinical trials has substantially increased their costs, but provides the possibility of improving the productivity of trials with a better selection of recruited patients. With the overall goal of creating a roadmap to improve translational design for future gynecological cancer trials and of defining translational goals, a main discussion was held during a brainstorming day of the Gynecologic Cancer InterGroup (GCIG) Translational Research Committee and overall conclusions are here reported. A particular emphasis was dedicated to the new frontier of the immunoprofiling of gynecological cancers. The discussion pointed out that to maximize patients’ benefit, translational studies should be integral to clinical trial design with standardization and optimization of procedures including a harmonization program of Standard Operating Procedures. Pathology-reviewed sample collection should be mandatory and ensured by dedicated funding. Biomarker validation and development should be made public and transparent to ensure rapid progresses with positive outcomes for patients. Guidelines/templates for patients’ informed consent are needed. Importantly for the public, recognized goals are to increase the involvement of advocates and to improve the reporting of translational data in a forum accessible to patients.
AU  - Bagnoli,M
AU  - Shi,TY
AU  - Gourley,C
AU  - Speiser,P
AU  - Reuss,A
AU  - Nijman,HW
AU  - Creutzberg,CL
AU  - Scholl,S
AU  - Negrouk,A
AU  - Brady,MF
AU  - Hasegawa,K
AU  - Oda,K
AU  - McNeish,IA
AU  - Kohn,EC
AU  - Oza,AM
AU  - MacKay,H
AU  - Millan,D
AU  - Bennett,K
AU  - Scott,C
AU  - Mezzanzanica,D
DO  - 10.3390/cells8030200
PY  - 2019///
SN  - 2073-4409
TI  - Gynecological cancers translational, research implementation, and harmonization: Gynecologic Cancer InterGroup consensus and still open questions
T2  - Cells
UR  - http://dx.doi.org/10.3390/cells8030200
UR  - http://hdl.handle.net/10044/1/68106
VL  - 8
ER  -
Download